Literature DB >> 15285713

Immunogen sequence: the fourth tier of AIDS vaccine design.

James I Mullins1, David C Nickle, Laura Heath, Allen G Rodrigo, Gerald H Learn.   

Abstract

While worldwide efforts to develop an effective HIV-1 vaccine are underway, the virus continues to spread, particularly in developing countries where the delivery of antiviral therapies presents formidable challenges. Vaccine research has largely focused on three general aspects: vectors, adjuvants, and immunization schedules. Our group favor the use of computational methods to design potential immunogens that capture the genetic and biological features of circulating viruses. These methods allow researchers to predict, in silico, the presence of potential glycosylation sites, humoral immune responses, and epitope coverage. This review shall compare three computational approaches for immunogen design: the consensus sequence, which has at each site the modal nucleotide or amino acid residue across a sequence alignment; the most recent common ancestor, the sequence estimated at the basal node of the clades seen in the HIV-1 phylogeny; and the center of tree method, which minimizes the evolutionary distance to all sequences in the data set.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285713     DOI: 10.1586/14760584.3.4.s151

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  24 in total

1.  Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development.

Authors:  Mariette F Ducatez; Justin Bahl; Yolanda Griffin; Evelyn Stigger-Rosser; John Franks; Subrata Barman; Dhanasekaran Vijaykrishna; Ashley Webb; Yi Guan; Robert G Webster; Gavin J D Smith; Richard J Webby
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

2.  Inferring viral population structures using heteroduplex mobility and DNA sequence analyses.

Authors:  Raj Shankarappa; James I Mullins
Journal:  J Virol Methods       Date:  2013-08-29       Impact factor: 2.014

3.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

4.  Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host.

Authors:  Joshua T Herbeck; David C Nickle; Gerald H Learn; Geoffrey S Gottlieb; Marcel E Curlin; Laura Heath; James I Mullins
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.

Authors:  Xintao Hu; Antonio Valentin; Frances Dayton; Viraj Kulkarni; Candido Alicea; Margherita Rosati; Bhabadeb Chowdhury; Rajeev Gautam; Kate E Broderick; Niranjan Y Sardesai; Malcolm A Martin; James I Mullins; George N Pavlakis; Barbara K Felber
Journal:  J Immunol       Date:  2016-10-12       Impact factor: 5.422

6.  Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.

Authors:  Sandrine L Hulot; Bette Korber; Elena E Giorgi; Nathan Vandergrift; Kevin O Saunders; Harikrishnan Balachandran; Linh V Mach; Michelle A Lifton; Giuseppe Pantaleo; Jim Tartaglia; Sanjay Phogat; Bertram Jacobs; Karen Kibler; Beatriz Perdiguero; Carmen E Gomez; Mariano Esteban; Margherita Rosati; Barbara K Felber; George N Pavlakis; Robert Parks; Krissey Lloyd; Laura Sutherland; Richard Scearce; Norman L Letvin; Michael S Seaman; S Munir Alam; David Montefiori; Hua-Xin Liao; Barton F Haynes; Sampa Santra
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

7.  Preparing for the availability of a partially effective HIV vaccine: some lessons from other licensed vaccines.

Authors:  Robert T Chen; Dale J Hu; Eileen Dunne; Michael Shaw; James I Mullins; Supachai Rerks-Ngarm
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

8.  Two-dimensional gel-based approaches for the assessment of N-Linked and O-GlcNAc glycosylation in human and simian immunodeficiency viruses.

Authors:  David R M Graham; Megan J Mitsak; Steven T Elliott; Dawn Chen; Stephen A Whelan; Gerald W Hart; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2008-12       Impact factor: 3.984

9.  Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.

Authors:  N A Doria-Rose; G H Learn; A G Rodrigo; D C Nickle; F Li; M Mahalanabis; M T Hensel; S McLaughlin; P F Edmonson; D Montefiori; S W Barnett; N L Haigwood; J I Mullins
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Sources of variation in ancestral sequence reconstruction for HIV-1 envelope genes.

Authors:  Howard A Ross; David C Nickle; Yi Liu; Laura Heath; Mark A Jensen; Allen G Rodrigo; James I Mullins
Journal:  Evol Bioinform Online       Date:  2007-01-13       Impact factor: 1.625

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.